Navigation Links
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
Date:11/2/2009

this patient population," said Leonardo Viana Nicacio, M.D., Director of Clinical Affairs for YM BioSciences. "The data are now shown to be reproducible in three separate studies, all of which reported nimotuzumab's characteristically benign toxicity profile. While the chemoradiotherapy and radiotherapy protocols in BEST differ from those commonly used in North America and Europe, treatments were consistent between the arms allowing for an appropriate assessment of nimotuzumab's activity and efficacy. These data, which suggest activity and durability similar to other anti-EGFR antibodies in this population, support the intended initiation of Phase III trials in this patient population."

A total of 92 patients were enrolled in the BEST trial, of which 76 were considered evaluable. The trial was sponsored by Biocon Ltd., the licensee from CIMAB S.A. for nimotuzumab in India. A poster describing 30-month data from this trial was presented at the 2009 ASCO Annual Meeting and is entitled: "A Phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (Stage III or IVa) inoperable head and neck cancer", by Reddy BK et al. (Citation: J Clin Oncol 27:15s, 2009; Abstract No: 6041; Session: Head and Neck Cancer).

The data presented at ASCO demonstrated that the addition of nimotuzumab to both the radiation and chemoradiation regimens improved the overall response rate, survival rate at 30 months, median progression-free survival and median overall survival. An unplanned, retrospective, combined group analysis of the nimotuzumab arms vs. the non-nimotuzumab arms demonstrated a significant difference in overall survival (p=0.0018) favoring nimotuzumab. The addition of nimotuzumab did not add to the severe toxicities of either regimen, with no Grade 3-4 skin toxicities observed. The authors concluded that the
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
2. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
3. OriGene Technologies Acquires Marligen Biosciences
4. Cytopia Merger with Toronto-based YM BioSciences Inc.
5. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
6. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
7. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
8. Neurocrine Biosciences Amends Corporate Headquarters Lease
9. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
10. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., , SAN MATEO, Calif., Nov. 24 /PRNewsw..., a biopharmaceutical company focused on developin...ies, announced today that Anthony DiTonno, Preside...esent at the 21st Annual Piper Jaffray Health Care...New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... The FBI recently approved...oratories participating in or generating DNA recor... Madison, WI USA (PRWEB) -- The FBI ...S System for use by laboratories participating in...Index System (NDIS). NDIS currently contains more ...
(Date:11/24/2009)..., , DUBLIN, November 24 /PRNewswire-Fi... the global specialty biopharmaceutical company, t...European Medicines Agency for,velaglucerase alfa, ...pment,for the treatment of Type 1 Gaucher disease....lucerase alfa that has been submitted, with previo...
(Date:11/24/2009)..., BOZEN,Italy,November24/PRNewswire/--HealthR...ointventurewithagroupofselected,investors.Thisrece...nameHealthRoboticsCanada,Inc.andwillmarket,install...ept,whichincludesthe,revolutionaryproductofferings...oticsCanadaInc.willalsoprovideassistanceonan"asnee...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
..., Aug. 19 Omeros Corporation, a,Seattle-based cli...h AS, a,Norwegian human antibody therapeutics comp...n agreement for the discovery and development of f...MASP-2, or mannan-binding,lectin-associated serine...,system via the lectin pathway and is linked to mu...
...olio of Transfusion Solutions Offers Choice, ...ROCKAWAY, N.J., Aug. 18 Biotest Diagnostics Corpo...based Biotest AG, a worldwide,supplier of traditio...s,that it has received final clearance from the U....keting its full line of traditional blood,bank rea...
... 4C Controls Inc. (OTCBB: FOUR.OB) today announc...(Ret.) Dr. Philip Hayden as its Vice President, Se... NEW YORK (Business Wire EON) A... after a distinguished career with the Federal Bur...years involved in many aspects of law enforcement ...
Other Biology Technology:Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 2Affitech and Omeros Enter Into Antibody Discovery and Development Agreement 3Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents 2Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4
(Date:11/24/2009)...rs to understanding how sounds associated with Nav...l or if they hear it at all. , The same type of...ses to detect flaws in the space shuttle,s behemot... peek inside the giant head of a whale. The scans ...of a whale,s hearing anatomy using a breakthrough ...
(Date:11/24/2009)... of Medical Toxicology (ACMT) have signed an agree...rnal of Medical Toxicology (JMT), the official jo...s previously published by the University of Pennsy...ogy , an international, peer-reviewed journal, is ... medical toxicology. The quarterly journal focuse...
(Date:11/24/2009)...) New research on bacterial communities throughou...table temporal patterns, suggesting that scientist...oring climate change in the polar regions. The stu... National Academy of Sciences Early Edition, show...fted synchronously over time, correlating with sea...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 1New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 2New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 3New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 4New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 5New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 6Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Desig 57642 1Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Desig 57642 2Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positive By Desig 57642 3AAA Members Save and Stay Healthy With Annual Eye Exams 57638 1AAA Members Save and Stay Healthy With Annual Eye Exams 57638 2AAA Members Save and Stay Healthy With Annual Eye Exams 57638 3
...Tulane National Primate Research Center has for th... agents in a vaginal gel protect the animals again... microbicide using compounds that inhibit the proc...ells could potentially provide a safe, effective a...men, according to study investigators. The study, ...
...anipulating the mosquitoes, sense of smell is the ...nderbilt University, that has been selected to rec...to Global Health. , The initiative, which was laun... just announced the selection of 43 "groundbreakin...ng countries that will receive a total of $436 mil...
...ty researchers have identified some of the key fac...d by multiple sclerosis (MS), complications of pre...he findings offer important clues about why the ne...ys that at least some forms of brain damage could ...st edition of the scientific journal Nature Medici...
Other Biology News:Vaginal gel may provide a new approach to HIV prevention 2Fighting malaria by manipulating mosquitoes' sense of smell 2Fighting malaria by manipulating mosquitoes' sense of smell 3Molecular Partners Required For Appropriate Neuronal Gene Repression 2Molecular Partners Required For Appropriate Neuronal Gene Repression 3Molecular Partners Required For Appropriate Neuronal Gene Repression 4
Z Amphetamine ELISA Kit, Single from Bio-Quant Inc.
Rat CGRP EIA Kit from Cayman Chemical
...RNA service provides the premium quality siRNAs yo...RNAs can be readily ordered online by providing ei...ng the sense and antisense siRNA sequences. (Also ... Pre-designed siRNAs, which are already designed f...
Custom siRNA, HPLC purified from Ambion
Biology Products: